Retinaldehyde Mimetics for White Adipose Browning
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for obesity and metabolic disorders, such as diabetes, are inadequate in effectively reducing visceral white fat and promoting beneficial brown adipose tissue formation, which is crucial for metabolic health.
Innovation Solution
Administering retinaldehyde increasing agents, such as inhibitors of the Aldh1a1 enzyme, to induce a brown adipose tissue-like phenotype in white adipose tissue, promoting thermogenesis and improving metabolic health markers like glucose and insulin tolerance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current treatments for obesity and metabolic disorders are used, then weight loss may occur, but visceral white fat reduction and brown adipose tissue formation are inadequate
Solution Approach 1:
The patent changes the biochemical parameter by increasing retinaldehyde levels through Aldh1a1 inhibition, which transforms the metabolic state of white adipose tissue. This parameter change induces browning of WAT, converting it into a more metabolically active state that resembles brown adipose tissue, thereby simultaneously achieving WAT reduction and BAT formation.
Solution Approach 2:
The patent introduces retinaldehyde as an intermediary substance that mediates the transformation of white adipose tissue. By administering retinaldehyde or its precursors (like retinol) or inhibitors of its degradation (Aldh1a1 inhibitors), retinaldehyde acts as a signaling molecule that triggers the browning program in WAT, leading to increased thermogenesis and metabolic health improvements.
2Reliability
If retinaldehyde increasing agents are administered to induce BAT-like phenotype in WAT, then thermogenesis and metabolic health improve, but the complexity of treatment mechanism increases
Solution Approach 1:
The patent extracts and targets a specific enzymatic step (Aldh1a1-mediated conversion of retinaldehyde to retinoic acid) in the retinoid metabolism pathway. By inhibiting this single enzyme, the treatment simplifies the approach compared to manipulating multiple pathways, while still achieving the desired effect of increasing retinaldehyde levels and inducing WAT browning.
Solution Approach 2:
Instead of directly administering retinaldehyde (which has limited stability and bioavailability), the patent inverts the approach by inhibiting the enzyme that degrades retinaldehyde (Aldh1a1). This indirect approach maintains higher levels of endogenous retinaldehyde and avoids some of the challenges associated with direct retinaldehyde administration, while achieving the same therapeutic effect.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively reduces white adipose tissue, increases body temperature, and enhances metabolic health markers, specifically by inducing a BAT-like phenotype in WAT, thereby addressing obesity and metabolic disorders without significantly reducing lean body mass.
Implementation Method 1
The enzyme Aldh1a1 catalyzes the conversion of Rald to retinoic acid
Implementation Method 2
retinaldehyde (Rald) promotes brown adipose tissue (BAT) phenotypes such as thermogenesis
Data Source
AI summary
The technology described herein is directed to methods of treating, e.g. obesity by administering retinaldehyde increasing agents.